PharmChem, Inc. (PCHM)
ValueMarkers Composite Index
30% below intrinsic value ($5)
PharmChem, Inc. (PCHM) — VMCI valuation read
PCHM prints VMCI 63/100 inside the Healthcare sector, where the median sits at 50. The 13-point above-median delta is the cleanest single-number summary of PharmChem, Inc.'s composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.
On PCHM, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.
**Investor frame.** PCHM trades at 24.0x earnings, 33% above the Healthcare median of 18.0x; that is the value line. ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 2.1x is the rate-sensitivity line to watch; that is the risk line for PharmChem, Inc. on the trailing financials.
PCHM fell 0.4% over the trailing 7 days, with a -13.6% read on a 30-day basis.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.